Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
Maren Hermanns-ClausenDieter MüllerJosephine KithinjiVerena AngererFlorian FranzFlorian EyerHartmud NeurathGesine LiebetrauVolker AuwärterPublished in: Clinical toxicology (Philadelphia, Pa.) (2017)
In this study, the valine derivative AB-CHMINACA and the tert-leucine derivative MDMB-CHMICA ("third generation of SCs") seem to be associated with more severe clinical toxicity than was previously reported in patients exposed to earlier generation SCs such as JWH-018. However, this observation needs to be confirmed with a larger cohort of patients with analytically confirmed abuse of third generation SCs. The rapid turnover of SCs on the drug market together with the occurrence of SCs such as AB-CHMINACA and MDMB-CHMICA is alarming, especially because of the unexpectedly high frequency of neuropsychiatric symptoms.
Keyphrases
- high frequency
- end stage renal disease
- transcranial magnetic stimulation
- ejection fraction
- newly diagnosed
- drug induced
- chronic kidney disease
- liver failure
- peritoneal dialysis
- prognostic factors
- emergency department
- depressive symptoms
- intensive care unit
- hepatitis b virus
- quantum dots
- aortic dissection
- electronic health record
- acute respiratory distress syndrome